1. Home
  2. LOCL vs ALXO Comparison

LOCL vs ALXO Comparison

Compare LOCL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Local Bounti Corporation

LOCL

Local Bounti Corporation

HOLD

Current Price

$1.15

Market Cap

25.6M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.14

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOCL
ALXO
Founded
2021
2015
Country
United States
United States
Employees
333
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.6M
68.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
LOCL
ALXO
Price
$1.15
$2.14
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.00
AVG Volume (30 Days)
22.7K
746.9K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$36.93
N/A
Revenue Next Year
$82.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.98
$0.41
52 Week High
$5.75
$2.66

Technical Indicators

Market Signals
Indicator
LOCL
ALXO
Relative Strength Index (RSI) 28.07 51.69
Support Level N/A $2.01
Resistance Level $2.75 $2.27
Average True Range (ATR) 0.14 0.20
MACD -0.02 -0.05
Stochastic Oscillator 16.06 21.88

Price Performance

Historical Comparison
LOCL
ALXO

About LOCL Local Bounti Corporation

Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: